We invest throughout the company life cycle – from the earliest creation through profitability – working closely with our teams to help reach their goals.
Click below for some of those stories:
Polaris has been a visionary partner in the founding and building of Visterra, working with our scientific team on the initial concept in the MIT Labs, forming the company, in-licensing the IP, hiring our first employees and serving as interim leadership in those early days. The firm has not only been our largest shareholder, but also a great champion, supporting a bold vision, leading our Board of Directors as we achieved each milestone and addressed every opportunity in building a platform that redefines the targeting of infectious disease. As a result of our partnership, Visterra has a strong investor syndicate that understands our science and our business and a management team that works exceptionally well together in breaking new ground. At each point where the company was ready to move to the next phase of development, the Polaris team has been there as an anchor, and will continue to be as we seek to help millions of patients worldwide.
– Brian Pereira, CEO, Visterra
After raising a successful Series A investment in 2009, we worked closely with Polaris to galvanize our Series B round in 2010-2011, which was a challenging fundraising environment globally. During this time, Polaris came to the table, recognizing the opportunity from both a scientific and business perspective and throwing support behind our team. It was a critical inflection point in our evolution and Polaris was there for us when others were not. Once on board, as an investor, Polaris was a “thought partner”, subscribing to our collective belief that the essence of strategy is choice. Together, throughout our growth, we explored many divergent paths before converging on the right one. This relationship allowed us to assess different options at the board level while supporting the team emotionally, spiritually and strategically. The result: Receptos was able to hit or exceed our milestones, and go public at a crucial time while developing important therapies to treat patients with debilitating diseases. Polaris played an important role in this success.
– Faheem Hasnain, President & CEO, Receptos 2010-2015
We were was a single, 104-bed psychiatric hospital looking for an investment partner who believed in our model to deliver specialty behavioral health programs to patients in under-served markets. Polaris quickly recognized Ascend’s opportunity in the $22 billion mental health arena where demand was outstripping supply. I chose to partner with them because of their commitment to our innovative services business model. It was a smart move. Polaris stepped up quickly at a time when our business was accelerating but the capital markets were challenged. Our behavioral health platform became validated with recognition of our programs for women, youth, active military affected by combat, and patients with co-occurring disorders. With Polaris as our largest investor, we expanded Ascend’s hospital chain to 5 states; our patient bed count went up more than 8 times; and we generated $200 million in annual revenue and $60 million in profits — all in 4 years. At the time of our sale to Universal Health Services, Ascend was the largest private psychiatric hospital provider in the country. Within months of the transaction, I chose Polaris as my lead investor in US Healthvest where we continue to do important work on behalf of psychiatric patients.
– Dr. Richard Kresch, CEO, Ascend & US Healthvest